Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib in early stage non-small cell lung cancer
NCT00087269Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Dec 2004
- Primary completion
- Apr 2006
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Started Dec 2004; status: terminated.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00087269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00087269.